Pulmo BioMed Co., Ltd. is a biotechnology pharmaceutical company. The R&D group of Pulmo BioMed led by Dr. Zhang has successfully developed a lot of medical products, such as NewEpi®, Vaginne® Intimate Gel, etc. NewEpi® wound healing product with active repair function won the 29th Taiwan Excellence Awards. It is granted by all major hospitals and has been widely used on the wound healing of surgery, burn, skin grafting, etc. Currently, Dr. Chang with extensive experience on researching and developing has obtained 20 domestic and foreign patents including Taiwan, USA, Germany, China and Japan.
The R&D group of Pulmo BioMed has been deeply involved in the field of protein and peptides for many years. Based on the understanding of protein function and structure, we have successfully developed the new protein drug – PulmoHeal® with three advantages "reversal of pulmonary fibrosis, short-term therapy, and high safety ". It not only reverses the progression of pulmonary fibrosis but also helps pulmonary function and structure return to normal. PulmoHeal® is a highly potential option for curing pulmonary fibrosis.
Because of the breakthrough of PulmoHeal® development, Pulmo BioMed Co., Ltd. was officially established in 2021 to develop products for the treatment of pulmonary fibrosis. Through the previous experience, we have global and local launch and commercialization success experience. Also, we have mature sales channels. With the previous successful model, we are confident that we can shorten the test schedule to speed up product launches.
Pulmonary fibrosis is scarring of lungs. The disease causes dyspnea and progressive deterioration of lung function in patients with a poor prognosis. Life expectancy of people with pulmonary fibrosis is generally less than five years. We dedicate to the development of the new protein drug - PulmoHeal® which can reverse the progression of pulmonary fibrosis and bring hopes for patients with pulmonary fibrosis.
Currently, we are seeking funding for PulmoHeal®. The data shows that the new protein drug - PulmoHeal® will become the first approved drug which can reverse the progression of pulmonary fibrosis.
We have confidence in the launch of this drug, and we invite you to participate in the development of PulmoHeal®!
The R&D group of Pulmo BioMed has been deeply involved in the field of protein and peptides for many years. Based on the understanding of protein function and structure, we have successfully developed the new protein drug – PulmoHeal® with three advantages "reversal of pulmonary fibrosis, short-term therapy, and high safety ". It not only reverses the progression of pulmonary fibrosis but also helps pulmonary function and structure return to normal. PulmoHeal® is a highly potential option for curing pulmonary fibrosis.
Because of the breakthrough of PulmoHeal® development, Pulmo BioMed Co., Ltd. was officially established in 2021 to develop products for the treatment of pulmonary fibrosis. Through the previous experience, we have global and local launch and commercialization success experience. Also, we have mature sales channels. With the previous successful model, we are confident that we can shorten the test schedule to speed up product launches.
Pulmonary fibrosis is scarring of lungs. The disease causes dyspnea and progressive deterioration of lung function in patients with a poor prognosis. Life expectancy of people with pulmonary fibrosis is generally less than five years. We dedicate to the development of the new protein drug - PulmoHeal® which can reverse the progression of pulmonary fibrosis and bring hopes for patients with pulmonary fibrosis.
Currently, we are seeking funding for PulmoHeal®. The data shows that the new protein drug - PulmoHeal® will become the first approved drug which can reverse the progression of pulmonary fibrosis.
We have confidence in the launch of this drug, and we invite you to participate in the development of PulmoHeal®!
Welcome to contact us!